Date:1/24/2013

0; Stock compensation expense0.090.080.350.29  Amortization of purchased intangible assets0.010.010.040.03  Impairment of intangible assets and licenses, net of tax0.020.080.020.08  Litigation settlement--0.23-  Tax benefit related to intercompany IP transaction--(0.03)-Non-GAAP measure of net income per share$
.20$
.14$
.31$
.44Shares used in computing basic net income (loss) per share66,37064,11365,81262,735Shares used in computing diluted net income (loss) per share68,78764,11365,81266,750  Impact of dilutive securities in periods of GAAP net loss and Non-GAAP net income5894,4803,888878Shares used in computing Non-GAAP diluted net income per share

69,37668,59369,70067,628 

CONTACTS:For Media Inquiries:For Investor Inquiries:Jared Tipton

Cepheid Corporate Communications

Tel: (408) 400 8377

communications@cepheid.com

Jacquie Ross

Cepheid Investor Relations

Tel: (408) 400 8329

investor.relations@cepheid.com
'/>"/>

SOURCE Cepheid Copyright©2012 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12
Related medicine technology :

1. Cepheid to Webcast Upcoming Financial Presentations
2. Cepheid Announces Executive Vice President Emerging Markets
3. Qmed, the Leading Global MedTech Industry Resource, Partners with Clarimed, to Provide the Medical Manufacturing and Healthcare Industry with FDA Reports on Adverse Events
4. Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed.
5. Kelyniam Global Inc. Reports Record Cranial Implant Revenues in the 1st Quarter of 2012
6. Varian Medical Systems Reports Results for Second Quarter of Fiscal Year 2012
7. Mylan Reports Q1 2012 Adjusted Diluted EPS of $0.52, an 18% Increase Over Prior Year Quarter
8. CryoLife Reports Record Quarterly Revenues in First Quarter of 2012
9. PAREXEL Reports Third Quarter Fiscal Year 2012 Financial Results
10. Luminex Corporation Reports First Quarter 2012 Results
11. Hospira Reports First-Quarter 2012 Results